CSL Vifor and Travere Therapeutics announced that Swissmedic has granted temporary marketing authorization for Filspari for the treatment of adults with primary IgA nephropathy, or IgAN, with a urine protein excretion of one g/day. Swissmedic approval was supported by results from the pivotal phase-III PROTECT study of Filspari in IgAN and follows full marketing approval by the FDA in September and conditional marketing authorization by the European Medicines Agency in April.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Disney initiated, Cisco upgraded: Wall Street’s top analyst calls
- Travere Therapeutics initiated with an Outperform at Scotiabank
- Travere Therapeutics price target raised to $30 from $12 at Evercore ISI
- Travere Therapeutics price target raised to $25 from $17 at Wedbush
- Travere Therapeutics price target raised to $20 from $18 at BofA